TERUFLEX BLOOD BAG SYSTEM WITH BLOOD SAMPLING ARM ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) AND OPTISOL (AS-5) RED CELL PRE United States - English - NLM (National Library of Medicine)

teruflex blood bag system with blood sampling arm anticoagulant citrate phosphate dextrose (cpd) and optisol (as-5) red cell pre

terumo corporation - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - trisodium citrate dihydrate 26.3 g in 1000 ml - issued 8/96 teruflex® blood bag system with blood sampling arm® cpd/optisol® solution read these instructions carefully before use. instructions for blood collection: use aseptic technique materials needed: venoject® ll tube holder (code p-1316r) venoject® ll multi-sample luer adapter (code mn *2000) venoject® ll plastic blood collection tubes (or equivalent glass or plastic evacuated blood collection tube) 1. confirm that all numbered tubing of each blood bag unit contains segment numbers. 2. make a loose knot in donor tubing below "y" unless alternate methods are used to seal tubing. 3. clamp donor tubing. 4. suspend primary bag as far as possible below the donor's arm. 5. apply blood pressure cuff or tourniquet to donor's arm. disinfect site of phlebotomy. if blood pressure cuff is used, inflate cuff to approximately 60 mmhg. 6. remove needle protector and perform phlebotomy. remove clamp to permit blood flow into primary bag. caution do not touch needle aft

TERUFLEX BLOOD BAG SYSTEM ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) AND OPTISOL RED CELL PRESERVATIVE (anticoagulant citrat United States - English - NLM (National Library of Medicine)

teruflex blood bag system anticoagulant citrate phosphate dextrose (cpd) and optisol red cell preservative (anticoagulant citrat

terumo corporation - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - trisodium citrate dihydrate 26.3 g in 1000 ml - revised 8/96 teruflex® blood bag system cpd/optisol® solution read these instructions before use. instructions for blood collection: use aseptic technique 1. confirm that all numbered tubing of each blood bag unit contains segment numbers. 2. make a loose knot in the donor tubing approximately 10 cm from needle unless alternate methods are used to seal tubing. 3. clamp donor tubing. 4. suspend primary bag as far as possible below the donor's arm. 5. apply blood pressure cuff or tourniquiet to donor's arm. disinfect site of phlebotomy. if blood pressure cuff is used, inflate cuff to 60 mmhg. 6. remove needle protector and perform phlebotomy. remove clamp to permit blood flow into primary bag. caution do not touch needle after removing the needle protector. 7. appropriately secure donor tubing to donor's arm. 8. mix blood with anticoagulant at several intervals during collection. 9. collect labeled volume of blood (+/- 10%). 10. tighten knot firmly after collection. clamp betwe

SODIUM NITROPRUSSIDE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium nitroprusside injection, solution, concentrate

akorn - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 50 mg in 2 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition

SODIUM PHENYLBUTYRATE powder United States - English - NLM (National Library of Medicine)

sodium phenylbutyrate powder

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

SODIUM PHENYLBUTYRATE powder United States - English - NLM (National Library of Medicine)

sodium phenylbutyrate powder

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

SODIUM ACETATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium acetate injection, solution, concentrate

fresenius kabi usa, llc - sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium cation 328 mg in 100 ml - sodium acetate injection, usp (4 meq per ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (4 meq per ml) is contraindicated in patients with hypernatremia or fluid retention.

SODIUM ACETATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium acetate injection, solution, concentrate

hospira, inc. - sodium acetate anhydrous (unii: nvg71zz7p0) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium acetate anhydrous 164 mg in 1 ml - sodium acetate injection, usp (2 meq/ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (2 meq/ml) is contraindicated in patients with hypernatremia or fluid retention.

SODIUM LACTATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium lactate injection, solution, concentrate

hospira, inc. - sodium lactate (unii: tu7hw0w0qt) (lactic acid, unspecified form - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37) - sodium lactate 5.6 g in 10 ml - sodium lactate injection, usp 50 meq (5 meq/ml), is primarily indicated, after dilution , as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients with restricted oral intake whose oxidative processes are not seriously impaired. it is not intended nor effective for correcting severe acidotic states which require immediate restoration of plasma bicarbonate levels. sodium lactate has no advantage over sodium bicarbonate and may be detrimental in the management of lactic acidosis. sodium lactate injection, usp 50 meq is contraindicated in patients suffering from hypernatremia or fluid retention. it should not be used in conditions in which lactate levels are increased (e.g., shock, congestive heart failure, respiratory alkalosis) or in which utilization of lactate is diminished (e.g., anoxia, beriberi). not for use in the treatment of lactic acidosis.

RE-SORB- sodium chloride, potassium phosphate, unspecified form, sodium citrate, potassium citrate, glycine, and dextrose powder United States - English - NLM (National Library of Medicine)

re-sorb- sodium chloride, potassium phosphate, unspecified form, sodium citrate, potassium citrate, glycine, and dextrose powder

zoetis inc. - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium phosphate, unspecified form (unii: b7862wz632) (potassium phosphate, unspecified form - unii:b7862wz632), sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c), dextrose (unii: iy9xdz35w2) (dextrose - unii:iy9xdz35w2) - sodium chloride 8.82 g in 64 g - re-sorb (glucose, glycine, and electrolytes for oral solution) is a readily absorbed source of fluids and electrolytes. it is a convenient and effective means of increasing absorption of water, energy sources, and electrolytes. re-sorb is indicated for use in the control of dehydration associated with diarrhea (scours) in calves, including veal calves. re-sorb may be used by the livestock owner as an early treatment at the first signs of scouring. it may also be used as follow-up treatment for the dehydrated calf following intravenous fluid therapy. re-sorb, because of its ready source of fluid and electrolytes, makes it an ideal first feed (upon arrival) for newly purchased or severely stressed calves.

SODIUM CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

sodium chloride injection, solution

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - sodium chloride injection, usp is indicated for parenteral restoration of sodium ion in patients with restricted oral intake.  sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome.  sodium chloride injection may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes. sodium chloride injection is contraindicated in patients with hypernatremia or fluid retention.